Trial Outcomes & Findings for Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children (NCT NCT00183391)
NCT ID: NCT00183391
Last Updated: 2018-06-06
Results Overview
ADHD-RS Total Score Attention Deficit Hyperactivity Disorder Rating Scale. Each item on the 18-item measure is scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms), yielding a possible total score of 0-54. Higher score indicates higher probability of diagnosis.
COMPLETED
PHASE4
232 participants
up to 14 weeks
2018-06-06
Participant Flow
Participant milestones
| Measure |
Atomoxetine Then Methylphenidate
Participants randomized to receive Atomoxetine until optimal response, then washed out and crossed-over to receive Methylphenidate.
|
Methylphenidate Then Atomoxetine
Participants randomized to receive Methylphenidate until optimal response, then washed out and crossed-over to receive Atomoxetine.
|
|---|---|---|
|
Block 1 - 5 Weeks
STARTED
|
108
|
124
|
|
Block 1 - 5 Weeks
COMPLETED
|
95
|
110
|
|
Block 1 - 5 Weeks
NOT COMPLETED
|
13
|
14
|
|
Crossover Placebo - 2 Weeks
STARTED
|
95
|
110
|
|
Crossover Placebo - 2 Weeks
COMPLETED
|
95
|
110
|
|
Crossover Placebo - 2 Weeks
NOT COMPLETED
|
0
|
0
|
|
Block 2 - 5 Weeks
STARTED
|
95
|
110
|
|
Block 2 - 5 Weeks
COMPLETED
|
91
|
108
|
|
Block 2 - 5 Weeks
NOT COMPLETED
|
4
|
2
|
Reasons for withdrawal
| Measure |
Atomoxetine Then Methylphenidate
Participants randomized to receive Atomoxetine until optimal response, then washed out and crossed-over to receive Methylphenidate.
|
Methylphenidate Then Atomoxetine
Participants randomized to receive Methylphenidate until optimal response, then washed out and crossed-over to receive Atomoxetine.
|
|---|---|---|
|
Block 1 - 5 Weeks
Withdrawal by Subject
|
13
|
14
|
|
Block 2 - 5 Weeks
Withdrawal by Subject
|
4
|
2
|
Baseline Characteristics
Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children
Baseline characteristics by cohort
| Measure |
Atomoxetine Then Methylphenidate
n=108 Participants
Participants randomized to receive Atomoxetine until optimal response, then washed out and crossed-over to receive Methylphenidate.
|
Methylphenidate Then Atomoxetine
n=124 Participants
Participants randomized to receive Methylphenidate until optimal response, then washed out and crossed-over to receive Atomoxetine.
|
Total
n=232 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
10.34 years
STANDARD_DEVIATION 2.61 • n=99 Participants
|
10.56 years
STANDARD_DEVIATION 2.83 • n=107 Participants
|
10.41 years
STANDARD_DEVIATION 2.72 • n=206 Participants
|
|
Sex: Female, Male
Female
|
27 Participants
n=99 Participants
|
36 Participants
n=107 Participants
|
63 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
81 Participants
n=99 Participants
|
88 Participants
n=107 Participants
|
169 Participants
n=206 Participants
|
PRIMARY outcome
Timeframe: up to 14 weeksPopulation: see participant flow section for participants that did not complete blocks
ADHD-RS Total Score Attention Deficit Hyperactivity Disorder Rating Scale. Each item on the 18-item measure is scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms), yielding a possible total score of 0-54. Higher score indicates higher probability of diagnosis.
Outcome measures
| Measure |
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
|
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
|
|---|---|---|
|
ADHD-RS Total Score
Block 1 Baseline Week 0
|
39.58 units on a scale
Standard Deviation 8.984
|
39.75 units on a scale
Standard Deviation 9.835
|
|
ADHD-RS Total Score
Block 1 End of Treatment Week 6
|
20.03 units on a scale
Standard Deviation 13.657
|
17.59 units on a scale
Standard Deviation 12.756
|
|
ADHD-RS Total Score
Block 2 Baseline Week 8
|
34.32 units on a scale
Standard Deviation 11.423
|
33.54 units on a scale
Standard Deviation 12.077
|
|
ADHD-RS Total Score
Blocks 2 End of Treatment Week 14
|
18.08 units on a scale
Standard Deviation 12.192
|
22.13 units on a scale
Standard Deviation 13.356
|
SECONDARY outcome
Timeframe: Measured at ends of treatments one and twoOutcome measures
| Measure |
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
|
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
|
|---|---|---|
|
Treatment Preference Survey
Treatment Preference of ATX
|
41.8 percentage of participants
|
27.4 percentage of participants
|
|
Treatment Preference Survey
Treatment Preference of MPH
|
50.5 percentage of participants
|
51.9 percentage of participants
|
SECONDARY outcome
Timeframe: up to 14 weeksPopulation: see participant flow section for participants that did not complete blocks
Attention deficit/hyperactivity disorder - hyperactivity/impulsivity (ADHD- H/I). Each item on the 18-item measure is scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms), yielding a possible total score of 0-27. Higher score indicates higher probability of diagnosis.
Outcome measures
| Measure |
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
|
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
|
|---|---|---|
|
ADHD - H/I
Block 1 Baseline Week 0
|
16.56 units on a scale
Standard Deviation 7.235
|
17.31 units on a scale
Standard Deviation 7.887
|
|
ADHD - H/I
Block 1 End of Treatment Week 6
|
7.82 units on a scale
Standard Deviation 7.159
|
7.24 units on a scale
Standard Deviation 7.083
|
|
ADHD - H/I
Block 2 Baseline 8
|
13.99 units on a scale
Standard Deviation 8.258
|
14.80 units on a scale
Standard Deviation 8.310
|
|
ADHD - H/I
Blocks 2 End of Treatment Week 14
|
6.67 units on a scale
Standard Deviation 5.818
|
8.87 units on a scale
Standard Deviation 7.651
|
SECONDARY outcome
Timeframe: up to 14 weeksPopulation: see participant flow section for participants that did not complete blocks
Each item on the 18-item measure is scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms), yielding a possible total score of 0-27. Higher score indicates higher probability of diagnosis.
Outcome measures
| Measure |
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
|
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
|
|---|---|---|
|
ADHD-RS Inattention
Block 1 Baseline Week 0
|
23.30 units on a scale
Standard Deviation 3.524
|
22.44 units on a scale
Standard Deviation 4.027
|
|
ADHD-RS Inattention
Block 1 End of Treatment Week 6
|
12.32 units on a scale
Standard Deviation 7.889
|
10.35 units on a scale
Standard Deviation 7.172
|
|
ADHD-RS Inattention
Block 2 Baseline Week 8
|
20.33 units on a scale
Standard Deviation 5.525
|
18.74 units on a scale
Standard Deviation 5.572
|
|
ADHD-RS Inattention
Blocks 2 End of Treatment Week 14
|
11.09 units on a scale
Standard Deviation 7.103
|
13.26 units on a scale
Standard Deviation 7.398
|
SECONDARY outcome
Timeframe: up to 14 weeksPopulation: see participant flow section for participants that did not complete blocks
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
Outcome measures
| Measure |
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
|
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
|
|---|---|---|
|
Clinical Global Impressions (CGI)- Severity
Block 1 Baseline Week 0
|
5.14 units on a scale
Standard Deviation .756
|
5.09 units on a scale
Standard Deviation .716
|
|
Clinical Global Impressions (CGI)- Severity
Block 1 End of Treatment Week 6
|
3.20 units on a scale
Standard Deviation 1.641
|
2.83 units on a scale
Standard Deviation 1.446
|
|
Clinical Global Impressions (CGI)- Severity
Block 2 Baseline Week 8
|
4.75 units on a scale
Standard Deviation .938
|
4.55 units on a scale
Standard Deviation 1.233
|
|
Clinical Global Impressions (CGI)- Severity
Blocks 2 End of Treatment Week 14
|
2.94 units on a scale
Standard Deviation 1.458
|
3.43 units on a scale
Standard Deviation 1.460
|
SECONDARY outcome
Timeframe: up to 14 weeksPopulation: see participant flow section for participants that did not complete blocks
Measure of social skills, higher score is better. This scale is based on t-scores and does not have psychometrics available.
Outcome measures
| Measure |
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
|
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
|
|---|---|---|
|
Social Skills Rating Scale (SSRS)- Parent Version
Block 1 Baseline Week 0
|
82.71 t-score
Standard Deviation 28.414
|
77.96 t-score
Standard Deviation 22.779
|
|
Social Skills Rating Scale (SSRS)- Parent Version
Block 1 End of Treatment Week 6
|
91.07 t-score
Standard Deviation 35.350
|
88.57 t-score
Standard Deviation 26.099
|
|
Social Skills Rating Scale (SSRS)- Parent Version
Block 2 Baseline Week 8
|
78.58 t-score
Standard Deviation 21.112
|
82.35 t-score
Standard Deviation 28.698
|
|
Social Skills Rating Scale (SSRS)- Parent Version
Blocks 2 End of Treatment Week 14
|
91.07 t-score
Standard Deviation 33.887
|
87.96 t-score
Standard Deviation 19.501
|
SECONDARY outcome
Timeframe: up to 14 weeksPopulation: see participant flow section for participants that did not complete blocks
Measure of conflict within the home over the past 24 hours. The CCI is a validated measure of family conflicts in the home and is completed by parents. It consists of 42 items (for boys) or 36 items (for girls) reflecting attention-seeking and conflictual behavior, as well as negativity and withdrawal. Items are scored as yes (1 point) or no (0 points). Mean score between 0 and 1 reported, with higher score indicating greater conflict.
Outcome measures
| Measure |
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
|
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
|
|---|---|---|
|
Child Conflict Index (CCI)
Block 1 Baseline Week 0
|
.3224 units on a scale
Standard Deviation .19841
|
.3385 units on a scale
Standard Deviation .19795
|
|
Child Conflict Index (CCI)
Block 1 End of Treatment week 6
|
.2386 units on a scale
Standard Deviation .21233
|
.1978 units on a scale
Standard Deviation .20251
|
|
Child Conflict Index (CCI)
Block 1 End of Treatment Week 8
|
.3526 units on a scale
Standard Deviation .20878
|
.3078 units on a scale
Standard Deviation .20744
|
|
Child Conflict Index (CCI)
Blocks 2 End of Treatment Week 14
|
.2118 units on a scale
Standard Deviation .20053
|
.2304 units on a scale
Standard Deviation .18978
|
SECONDARY outcome
Timeframe: up to 14 weeksPopulation: see participant flow section for participants that did not complete blocks
CPT Commissions, impulsive responses, higher score is worse. This scale is based on t-scores and does not have psychometrics available.
Outcome measures
| Measure |
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
|
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
|
|---|---|---|
|
Continuous Performance Test (CPT)
Block 1 Baseline Week 0
|
51.3277 T-scores
Standard Deviation 9.73401
|
52.8976 T-scores
Standard Deviation 9.36961
|
|
Continuous Performance Test (CPT)
Block 1 End of Treatment Week 6
|
51.7005 T-scores
Standard Deviation 9.57790
|
51.1713 T-scores
Standard Deviation 9.96929
|
|
Continuous Performance Test (CPT)
Block 2 Baseline Week 8
|
59.8788 T-scores
Standard Deviation 8.82849
|
51.2159 T-scores
Standard Deviation 9.00827
|
|
Continuous Performance Test (CPT)
Blocks 2 End of Treatment Week 14
|
50.0763 T-scores
Standard Deviation 11.16765
|
49.1616 T-scores
Standard Deviation 10.02259
|
SECONDARY outcome
Timeframe: up to 14 weeksPopulation: see participant flow section for participants that did not complete blocks
Children's Sleep Problems Severity, sum of scores, higher is worse.The scale assessed contains 16 items, each scored 0 to 3, with 0 representing no problems and 3 representing daily problems. total range from 0 to 48. This score does not have psychometrics available.
Outcome measures
| Measure |
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
|
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
|
|---|---|---|
|
Children's Sleep Questionnaire
Block 1 Baseline Week 0
|
5.14 units on a scale
Standard Deviation .756
|
5.09 units on a scale
Standard Deviation .716
|
|
Children's Sleep Questionnaire
Block 1 End of Treatment Week 6
|
3.20 units on a scale
Standard Deviation 1.641
|
2.83 units on a scale
Standard Deviation 1.446
|
|
Children's Sleep Questionnaire
Block 2 Baseline Week 8
|
4.75 units on a scale
Standard Deviation .938
|
4.55 units on a scale
Standard Deviation 1.233
|
|
Children's Sleep Questionnaire
Blocks 2 End of Treatment Week 14
|
2.94 units on a scale
Standard Deviation 1.458
|
3.43 units on a scale
Standard Deviation 1.460
|
SECONDARY outcome
Timeframe: up to 14 weeksPopulation: see participant flow section for participants that did not complete blocks
Affective problems. This scale consists of 8 items, scored 0-3, with 0 representing no problems and 3 representing extreme problems. This analysis presents sum of scores, higher is worse. Full range from 0 to 24. This score does not have psychometrics available.
Outcome measures
| Measure |
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
|
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
|
|---|---|---|
|
Assessment of Affective Range (AAR)
Block 1 Baseline Week 0
|
11.2609 units on a scale
Standard Deviation 2.85251
|
10.6905 units on a scale
Standard Deviation 3.44309
|
|
Assessment of Affective Range (AAR)
Block 1 End of Treatment Week 6
|
10.6889 units on a scale
Standard Deviation 2.83495
|
10.8257 units on a scale
Standard Deviation 2.77170
|
|
Assessment of Affective Range (AAR)
Block 2 Baseline Week 8
|
9.7108 units on a scale
Standard Deviation 2.99402
|
10.1400 units on a scale
Standard Deviation 3.06831
|
|
Assessment of Affective Range (AAR)
Blocks 2 End of Treatment Week 14
|
10.9886 units on a scale
Standard Deviation 2.69736
|
10.9286 units on a scale
Standard Deviation 3.02652
|
SECONDARY outcome
Timeframe: up to 14 weeksPopulation: see participant flow section for participants that did not complete blocks
Modified Yale Global Tic Severity Scale, sum, higher is worse. This score does not have psychometrics available. The Yale Global Tic Severity Scale (YGTSS) is a semistructured clinician-rated instrument that assesses the severity and frequency of motor and phonic tics over the previous week. Five index scores are obtained during the assessment, where higher scores indicate greater frequency or severity. These indices are: Total Motor Tic Score (0-25), Total Phonic Tic Score (0-25), Total Tic Score (0-50) Overall Impairment Rating (0-50).
Outcome measures
| Measure |
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
|
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
|
|---|---|---|
|
Tics: Total Motor
Block 1 Baseline Week 0
|
.196 units on a scale
Standard Deviation .7727
|
.111 units on a scale
Standard Deviation .4297
|
|
Tics: Total Motor
Block 1 End of Treatment Week 6
|
.053 units on a scale
Standard Deviation .2941
|
1.342 units on a scale
Standard Deviation 11.3544
|
|
Tics: Total Motor
Block 2 Baseline Week 8
|
.000 units on a scale
Standard Deviation .0000
|
.214 units on a scale
Standard Deviation .8494
|
|
Tics: Total Motor
Blocks 2 End of Treatment Week 14
|
.160 units on a scale
Standard Deviation .7656
|
.143 units on a scale
Standard Deviation .6686
|
SECONDARY outcome
Timeframe: up to 14 weeksPopulation: see participant flow section for participants that did not complete blocks
Modified Yale Global Tic Severity Scale, sum, higher is worse. This score does not have psychometrics available. The Yale Global Tic Severity Scale (YGTSS) is a semistructured clinician-rated instrument that assesses the severity and frequency of motor and phonic tics over the previous week. Five index scores are obtained during the assessment, where higher scores indicate greater frequency or severity. These indices are: Total Motor Tic Score (0-25), Total Phonic Tic Score (0-25), Total Tic Score (0-50) Overall Impairment Rating (0-50).
Outcome measures
| Measure |
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
|
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
|
|---|---|---|
|
Tics: Total Phonic
Block 2 Baseline Week 8
|
.039 units on a scale
Standard Deviation .1960
|
.057 units on a scale
Standard Deviation .2892
|
|
Tics: Total Phonic
Block 1 Baseline Week 0
|
.161 units on a scale
Standard Deviation .5649
|
.028 units on a scale
Standard Deviation .1655
|
|
Tics: Total Phonic
Block 1 End of Treatment Week 6
|
.018 units on a scale
Standard Deviation .1325
|
1.329 units on a scale
Standard Deviation 11.3542
|
|
Tics: Total Phonic
Blocks 2 End of Treatment Week 14
|
.060 units on a scale
Standard Deviation .3136
|
.016 units on a scale
Standard Deviation .1260
|
SECONDARY outcome
Timeframe: up to 14 weeksPopulation: see participant flow section for participants that did not complete blocks
Modified Yale Global Tic Severity Scale, sum, higher is worse. This score does not have psychometrics available. The Yale Global Tic Severity Scale (YGTSS) is a semistructured clinician-rated instrument that assesses the severity and frequency of motor and phonic tics over the previous week. Five index scores are obtained during the assessment, where higher scores indicate greater frequency or severity. These indices are: Total Motor Tic Score (0-25), Total Phonic Tic Score (0-25), Total Tic Score (0-50) Overall Impairment Rating (0-50).
Outcome measures
| Measure |
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
|
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
|
|---|---|---|
|
Tics: Total Impairment
Block 1 Baseline Week 0
|
5.304 units on a scale
Standard Deviation 22.4936
|
.292 units on a scale
Standard Deviation 1.8571
|
|
Tics: Total Impairment
Block 1 End of Treatment Week 6
|
1.737 units on a scale
Standard Deviation 13.1129
|
.132 units on a scale
Standard Deviation 1.1471
|
|
Tics: Total Impairment
Block 2 Baseline Week 8
|
.000 units on a scale
Standard Deviation .0000
|
.643 units on a scale
Standard Deviation 3.1762
|
|
Tics: Total Impairment
Blocks 2 End of Treatment Week 14
|
.500 units on a scale
Standard Deviation 2.9014
|
.397 units on a scale
Standard Deviation 2.2543
|
SECONDARY outcome
Timeframe: up to 14 weeksPopulation: see participant flow section for participants that did not complete blocks
Systolic blood pressure - the amount of pressure in arteries during contraction of the heart muscle Normal range varies by age, sex, height and weight and can range from 80mm Hg to 130mmHg
Outcome measures
| Measure |
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
|
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
|
|---|---|---|
|
Vital Signs - Systolic Blood Pressure
Block 1 Baseline Week 0
|
101.11 mm HG
Standard Deviation 11.877
|
101.60 mm HG
Standard Deviation 11.261
|
|
Vital Signs - Systolic Blood Pressure
Block 1 End of Treatment Week 6
|
102.10 mm HG
Standard Deviation 12.442
|
103.29 mm HG
Standard Deviation 12.374
|
|
Vital Signs - Systolic Blood Pressure
Block 2 Baseline Week 8
|
99.74 mm HG
Standard Deviation 12.199
|
101.29 mm HG
Standard Deviation 12.629
|
|
Vital Signs - Systolic Blood Pressure
Blocks 2 End of Treatment Week 14
|
102.34 mm HG
Standard Deviation 11.797
|
102.51 mm HG
Standard Deviation 11.488
|
SECONDARY outcome
Timeframe: up to 14 weeksPopulation: see participant flow section for participants that did not complete blocks
Diastole blood pressure - blood pressure when the heart muscle is between beats. normal range varies by age, sex, height and weight and can range from 34mm Hg to 90mmHg
Outcome measures
| Measure |
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
|
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
|
|---|---|---|
|
Vital Signs - Diastolic Blood Pressure
Block 1 Baseline Week 0
|
61.78 mm HG
Standard Deviation 8.773
|
61.26 mm HG
Standard Deviation 7.882
|
|
Vital Signs - Diastolic Blood Pressure
Block 1 End of Treatment Week 6
|
64.58 mm HG
Standard Deviation 8.638
|
62.77 mm HG
Standard Deviation 8.609
|
|
Vital Signs - Diastolic Blood Pressure
Block 2 Baseline Week 8
|
62.33 mm HG
Standard Deviation 7.835
|
61.28 mm HG
Standard Deviation 8.442
|
|
Vital Signs - Diastolic Blood Pressure
Blocks 2 End of Treatment Week 14
|
62.82 mm HG
Standard Deviation 7.325
|
65.44 mm HG
Standard Deviation 8.699
|
SECONDARY outcome
Timeframe: up to 14 weeksPopulation: see participant flow section for participants that did not complete blocks
Heartbeats per minute. Range varies from 50-205 depending on age and level of activity.
Outcome measures
| Measure |
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
|
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
|
|---|---|---|
|
Vital Signs - Pulse
Block 1 Baseline Week 0
|
78.20 beats per minute
Standard Deviation 12.927
|
77.49 beats per minute
Standard Deviation 12.365
|
|
Vital Signs - Pulse
Block 1 End of Treatment Week 6
|
84.46 beats per minute
Standard Deviation 14.697
|
82.05 beats per minute
Standard Deviation 12.915
|
|
Vital Signs - Pulse
Block 2 Baseline Week 8
|
82.96 beats per minute
Standard Deviation 13.931
|
81.30 beats per minute
Standard Deviation 12.683
|
|
Vital Signs - Pulse
Blocks 2 End of Treatment Week 14
|
84.85 beats per minute
Standard Deviation 13.314
|
84.31 beats per minute
Standard Deviation 13.095
|
SECONDARY outcome
Timeframe: up to 14 weeksPopulation: data not collected
Measure of socioeconomic status, score calculated from averaging likert responses, lower = worse
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: up to 14 weeksPopulation: data not collected
Standardized measure of ADHD symptoms and severity, norm referenced T scores, higher = worse
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: up to 14 weeksPopulation: data not collected
Standardized measure of ADHD symptoms and severity, norm referenced T scores, higher = worse
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Measured at screeningPopulation: data not collected
CBCL Total Score, measure of psychosocial problems, higher is worse.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: up to 14 weeksPopulation: data not collected
Measure of social skills, higher score is better. This scale is based on t-scores and does not have psychometrics available.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: up to 14 weeksPopulation: data not collected
Measure of fluency in performance of simple mathematics, sum, lower = worse
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Measured daily throughout the studyPopulation: data not collected
Measure of physical activity
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Measured daily throughout the studyPopulation: data not collected
Questionnaire, qualitative
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Measured at screeningPopulation: data not collected
Questionnaire, qualitative designed to collect family history, prenatal environmental influences, and developmental history.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: up to 14 weeksPopulation: data not collected
Questionnaire, qualitative assesses symptoms of rebound (moodiness, irritability, aggression, and ADHD symptoms) when the medication wears off at night.
Outcome measures
Outcome data not reported
Adverse Events
Block 1 ATX
Block 1 MPH
Block 2 ATX
Block 2 MPH
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Block 1 ATX
n=108 participants at risk
Block 1 first four weeks received Atomoxetine
|
Block 1 MPH
n=124 participants at risk
Block 1 first four weeks received Methylphenidate
|
Block 2 ATX
n=95 participants at risk
Block 2 (weeks 8 to 13) received Atomoxetine
|
Block 2 MPH
n=110 participants at risk
Block 2 (weeks 8 to 13) received Methylphenidate
|
|---|---|---|---|---|
|
General disorders
Insomnia
|
4.6%
5/108
|
12.9%
16/124
|
3.2%
3/95
|
12.7%
14/110
|
|
Psychiatric disorders
Aggression
|
5.6%
6/108
|
4.8%
6/124
|
5.3%
5/95
|
3.6%
4/110
|
|
Gastrointestinal disorders
Appetite Loss
|
6.5%
7/108
|
7.3%
9/124
|
7.4%
7/95
|
3.6%
4/110
|
|
Psychiatric disorders
Irritability
|
5.6%
6/108
|
3.2%
4/124
|
5.3%
5/95
|
2.7%
3/110
|
Additional Information
Dr. Jeffrey H Newcorn
Icahn School of Medicine at Mount Sinai
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place